Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

PPP-3 > Immunosuppressants for Immuno exam > Flashcards

Immunosuppressants for Immuno exam Flashcards

1
Q

What are the three major indications for immunosuppressants?

A
  1. Organ Transplant Rejection
  2. Chronic inflammatory diseases
  3. Autoimmune diseases
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the major adverse effects of immunosuppressants?

A

Increased risk for infections and malignancies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is the MOA of prednisone?

A
  • Antinflammatory effects at lower doses: decrease synthesis of inflammatory mediators and decrease expression of adhesion molecules for extravasation
  • Anti-inflammatory +immunosuppress effects at higher doses: increase expression of proteins that promote apoptosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the major indications of prednisone?

A
  • Inflammatory disorders like osteoarthritis
  • Systemic inflammatory autoimmune diseases like RA, SLE, IBD
  • Organ transplant rejection
  • GVHD prophylaxis following bone marrow transplant
  • T cell mediated hypersensitivities like poison oak and chronic asthma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are side effects of prednisone?

A

Cushings syndrome and caution for adrenal suppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Cyclosporine (TCR signaling inhibitors) MOA

A

Inhibit T cell intracellular signal 1 that is initiated by CD3 after TCR and co-receptor bind to p-MHC (signal 1) –> inhibits calcineurin which decreases T cell activation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Cyclosporine indications

A
  • Systemic autoimmune disease like RA
  • Organ transplant rejection prophylaxis
  • GVHD prophylaxis following bone marrow transplant
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Cyclosporine specific AEs

A
  • Nephrotoxicity
  • Hypertension
  • Neurotoxicity
  • Electrolyte abnormalities
  • Gingival hyperplasia
  • Hirsutism
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Belatacept MOA

A

CTLA-4 binds to B7 and prevents T-cell activation via CD28 via signal 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Belatacept indication

A

Organ transplant rejection prophylaxis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Belatacept AEs

A

Typical class effect (increased risk of infections and malignancies) and could cause PTLD or post-transplant lymphoproliferative disorder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Natalizumab MOA

A

Blocks VLA-4 and prevents extravasation of effector T cells into inflamed tissue (brain in MS, joints in RA, colon in IBD)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Natalizumab indication

A

Autoimmune diseases like MS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Natalizumab adverse effects

A

Typical class effect (increased risk of infections and malignancies) and increased risk of PML or progressive multifocal leukoencephalopathy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Rituximab (Anti-CD20 mab) MOA

A

Binds CD20 on B cells then initiates complement or ADCC to kill B cells which decreases circulating B cells & decreases absorption that mediates part of the inflammatory process of disease –> also kills tumor B-cells as well as normal B cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Indications for rituximab

A
  • Relapsing/remitting MS
  • Antibody-mediated systemic autoimmune complex diseases like RA and SLE
  • Non-Hodgkins B cell lymphoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Rituximab AEs

A
  • Hepatitis B reactivation
  • Increased risk of progressive multifocal encephalopathy (PME)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Infliximab (Anti-TNF mab) MOA

A

Prevents TNF from activating its R and decreases inflammatory effects and innate response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Infliximab Indications

A
  • Some systemic autoimmune diseases like RA and IBD
  • Psoriatic arthritis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Infliximab AE

A

Increased risk of TB as well as other infections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

T/F: Adalimumab is a mouse antibody

A

False, it is a TNF humanized antibody because it has the suffix mumab

22
Q

Cetuximab (anti-EGFR mAb) MOA

A

IgG binding to cell EGFR causes initiation of ADCC to allow NK cells to kill tumor cells –> also blocks EGFR signaling which impairs tumor growth and survival

23
Q

Cetuximab indications

A

Used in tumors that overexpress EGFR as a cancer driver mutation

24
Q

Cetuximab side effects

A

Rash and diarrhea

25
Anakinra MOA
Prevents IL-1 receptor activation and decreases it
26
Anakinra indication
Hereditary fever syndromes like FMF
27
Anakinra AEs
Class effects only (increase risk of infections and malignancies)
28
Tocilizumab MOA
Binds to IL-6 receptor and decreases it which leads to lower inflammation
29
Tocilizumab indications
RA
30
Tocilizumab AEs
Class effects (increased risk of infections and malignancy)
31
Trastuzumab MOA
mAB to HER-2 and blocks HER-2 signaling (leads to impaired tumor cell growth/survival) and has IgG mAB bind to HER-2 (initiates ADCC to allow NK cells to kill tumor cells)
32
Trastuzumab indications
Tumors overexpressing HER-2
33
Anti-CTLA-4 mAB MOA
Prevents inhibition of clonal expansion of T cells and allows a stronger T cell response against cancer and other tissues
34
Anti-CTLA-4 indications
Melanoma
35
Anti-PD1 mAB MOA
Prevents the inhibitory signal and allows CD8 T cells to kill the cancer cells
36
Anti-PD1 indications
Many solid and hematologic cancers like melanoma, colon cancer, lung cancer, lymphoma
37
Anti-CTLA and anti-PD1 adverse effect
Excessive T cell mediated inflammation in various organs
38
Albuterol (B2 agonist) MOA
Stimulates B cell receptors on airway SM and causes bronchodilation but less effective with chronic inflammation
39
Albuterol indications
Acute allergic asthma
40
Albuterol AEs
- Tremor - CNS effects like anxiety - Increased HR
41
Epinephrine (mixed a/B agonist) MOA
- Stimulates B2 receptors on airway smooth muscle which causes bronchodilation - Stimulates a1 receptors on vascular SM which increases SVR and blood pressure - stimulates a1 receptors on ECs which reclose tight junctions and decrease edema
42
Epinephrine indications
Anaphylaxis
43
Epinephrine AEs
Increased HR and cardiac arrhythmias
44
Omalizumab (anti-IgE mAB) MOA
Binds Fc of soluble IgE and decreases binding to FCE receptors on mast cell (early response) and eosinophils (delayed response)
45
Omalizumab indications
1. Moderate to severe allergic asthma 2. Chronic idiopathic urticaria
46
Chlorpheniramine (1st gen) and fexofenadine (2nd gen) ( both are H1-R antagonists) MOA
Blocks H1-R and decreases histamine mediated symptoms caused by HM release from mast cells
47
H1-R antagonist indications
Allergic rhinitis and urticaria (poison ivy or oak)
48
Mepolizumab (anti-IL-5 mAB) MOA
Binds IL-5 and decreases activation of its receptor which leads to decreased activation/recruitment of eosinophils
49
Mepolizumab indications
Severe asthma and chronic allergic dermatitis
50
Montelukast (LT R antagonist) MOA
Blocks CysLT receptors and decreases LT symptoms
51
Montelukast indications
Allergic rhinitis and chronic asthma

PPP-3 (21 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions